Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia

References

• Assouline S, Culjkovic B, Cocolakis E, et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. 2009;114:257–260.
   PubMed Web of Science ®Google Scholar
• Topisirovic I, Guzman ML, McConnell MJ, et al. Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol. 2003;23:8992–9002.
   PubMed Web of Science ®Google Scholar
• Topisirovic I, Kentsis A, Perez JM, et al. Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. Mol Cell Biol. 2005;25:1100–1112.
   PubMed Web of Science ®Google Scholar
• Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31:3889–3897.
   PubMed Web of Science ®Google Scholar
• Horita H, Frankel AE, Thorburn A. Acute myeloid leukemia-targeted toxin activates both apoptotic and necroptotic death mechanisms. PLoS One. 2008;3:e3909.
   PubMed Web of Science ®Google Scholar
• Robert F, Carrier M, Rawe S, et al. Altering chemosensitivity by modulating translation elongation. PLoS One. 2009;4:e5428.
   PubMed Web of Science ®Google Scholar
• Chen Y, Hu Y, Michaels S, et al. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia. 2009;23:1446–1454.
   PubMed Web of Science ®Google Scholar
• Allan EK, Holyoake TL, Craig AR, et al. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia. 2011;25:985–994.
   PubMed Web of Science ®Google Scholar
• Gurel G, Blaha G, Moore PB, et al. U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol. 2009;389:146–156.
   PubMed Web of Science ®Google Scholar
• Jin J, Wang JX, Chen FF, et al. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2013;14:599–608.
   PubMed Web of Science ®Google Scholar
• Robichaud N, del RSV, Huor B, et al. Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene. 2015;34:2032–2042.
   PubMed Web of Science ®Google Scholar
• Bitterman PB, Polunovsky VA. eIF4E-mediated translational control of cancer incidence. Biochim Biophys Acta. 2015;1849:774–780.
   PubMed Web of Science ®Google Scholar
• Gu Y, Zhou H, Gan Y, et al. Small-molecule induction of phospho-eIF4E sumoylation and degradation via targeting its phosphorylated serine 209 residue. Oncotarget. 2015;6:15111–15121.
   PubMed Web of Science ®Google Scholar
• Hu L, Cao D, Li Y, et al. Resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cells-mediated cytolysis through NKG2D ligands and TRAIL receptors. Cancer Biol Ther. 2012;13:516–526.
   PubMed Web of Science ®Google Scholar
• Fuchs D, Daniel V, Sadeghi M, et al. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun. 2010;394:1098–1104.
   PubMed Web of Science ®Google Scholar
• Jin J, Jiang DZ, Mai WY, et al. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia. 2006;20:1361–1367.
   PubMed Web of Science ®Google Scholar
• Mrozek K, Tanner SM, Heinonen K, et al. Molecular cytogenetic characterization of the KG-1 and KG-1a acute myeloid leukemia cell lines by use of spectral karyotyping and fluorescence in situ hybridization. Genes Chromosom Cancer. 2003;38:249–252.
   PubMed Web of Science ®Google Scholar
• Kentsis A, Topisirovic I, Culjkovic B, et al. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA. 2004;101:18105–18110.
   PubMed Web of Science ®Google Scholar
• Smith CR Jr, Powell RG, Mikolajczak KL. The genus Cephalotaxus: source of homoharringtonine and related anticancer alkaloids. Cancer Treat Rep. 1976;60:1157–1170.
   PubMedGoogle Scholar
• Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007;109:248–255.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 1995;86:3322–3326.
   PubMed Web of Science ®Google Scholar
• Hagner PR, Schneider A, Gartenhaus RB. Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood. 2010;115:2127–2135.
   PubMed Web of Science ®Google Scholar
• Strudwick S, Borden KL. The emerging roles of translation factor eIF4E in the nucleus. Differentiation. 2002;70:10–22.
   PubMed Web of Science ®Google Scholar
• Culjkovic B, Topisirovic I, Skrabanek L, et al. eIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol. 2006;175:415–426.
   PubMed Web of Science ®Google Scholar
• Furic L, Rong L, Larsson O, et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci USA. 2010;107:14134–14139.
   PubMed Web of Science ®Google Scholar
• Hay N. Mnk earmarks eIF4E for cancer therapy. Proc Natl Acad Sci USA. 2010;107:13975–13976.
   PubMed Web of Science ®Google Scholar
• Wendel HG, Silva RL, Malina A, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007;21:3232–3237.
   PubMed Web of Science ®Google Scholar
• Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 2006;66:10959–10966.
   PubMed Web of Science ®Google Scholar
• Segal D, Michaels S, Li S, et al. Omacetaxine induces the rapid loss of anti-apoptotic short-lived proteins in BCR-ABL positive cells. Presented at the 100th annual meeting the American Association for Cancer Research; April 2009; Denver, CO.
   Google Scholar
• Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood. 2009;114:5034–5043.
   PubMed Web of Science ®Google Scholar